Русский
ProstaNorm®: application and effectiveness of use in patients with ureteral stent catheter
DOI: https://dx.doi.org/10.18565/nephrology.2022.3.77-82
Rusanova E.V., Vasilenko I.A., Bychkova N.V., Erofeeva S.B., Schelkova V.V., Voskoboynikova A.K., Kolkhir V.K.
1) M.F. Vladimirsky Moscow Regional Clinical and Research Institute (MONIKI), Moscow, Russia; 2) Russian State University named after A.N. Kosygin, Moscow, Russia; 3) АO FPК PharmVILAR, Moscow, Russia
Materials and methods: 40 female patients with urolithiasis and ureteral stent catheters were enrolled in the prospective study after endoscopic X-ray endourologic surgery (contact ureterolithotripsy (CULT)). The dynamics of a number of clinical and laboratory parameters was estimated after prescription of phytopreparation ProstaNorm® in the form of monotherapy in a continuous mode with the duration of use of 1 month.
Results: against the background of the treatment after stent removal (2 weeks from the beginning of the study) as compared to the control group a decrease of micturation frequency by 30% on the average – 6,0±1,8, regression of erythrocyturia and leukocyturia was noted. One month after treatment had begun bacteriological examination of urine showed absence of microbial growth in 25% of cases.
Conclusions: prostaNorm® has a good antibacterial effect and can be recommended for long-term treatment and prophylactic therapy in patients with catheter-associated urinary infection.
About the Autors
Elena V. Rusanova – Ph.D. (Med.), Leading Researcher of the Laboratory of Biomedical Research Methods, M.F. Vladimirsky Moscow Regional Clinical and Research Institute (MONIKI), 61/2, Schepkina str., Moscow, 129110; Associate Professor of the Department of Inorganic and Analytical Chemistry, Russian State University named after A.N. Kosygin, 33/1, Sadovnicheskaya ul., Moscow, 115035, e-mail: e.rysanova@monikiweb.ru
ORCID: https://orcid.org/0000-0002-7996-2944
Irina A. Vasilenko – Dr. Sci. (Med.), Professor, Head of the Laboratory of Biomedical Research Methods, M.F. Vladimirsky Moscow Regional Clinical and Research Institute (MONIKI), 61/2, Schepkina str., Moscow. 129110; Professor of the Department of Inorganic and Analytical Chemistry, Russian State University named after A.N. Kosygin, 33/1, Sadovnicheskaya ul., Moscow, 115035; e-mail: vasilenko.ia0604@yandex.ru
ORCID: https://orcid.org/0000-0002-6374-9786
Natal'ya V. Bychkova – Ph.D. (Med.), Senior Researcher of the Department of Urology, Associate Professor of the Department of Urology, M.F. Vladimirsky Moscow Regional Clinical and Research Institute (MONIKI), 61/2, Schepkina str., Moscow, 129110; e-mail: nat.uro@mail.ru
ORCID: https://orcid.org/0000-0001-9082-5978
Svetlana B. Erofeeva – к.м.н., Head of Experimental and Clinical Research Department, M.F. Vladimirsky Moscow Regional Clinical and Research Institute (MONIKI), 61/2, Schepkina str., Moscow, 129110; e-mail: erofsb@mail.ru
ORCID: https://orcid.org/ 0000-0002-6317-2868
Victoria V. Schelkova – Researcher of the Laboratory of Biomedical Research Methods, M.F. Vladimirsky Moscow Regional Clinical and Research Institute (MONIKI), 61/2, Schepkina str., Moscow, 129110; e-mail: victoria.shchelkova@yandex.ru
ORCID: https://orcid.org/0000-0001-9082-5978
Alexandra K. Voskoboynikova - Deputy General director of AO FPК PharmVILAR, 7, Grina st., Moscow, 117216; e-mail: alexandra.vo@pharmvilar.ru
Vladimir K. Kolkhir – Dr. Sci. (Med.), Chief Researcher of the Department of Experimental Pharmacology of FSBI "VILAR", Deputy General director of AO FPK PharmVILAR, 7, Grina st., Moscow, 117216, e-mail: kolkhir@pharmvilar.ru
Similar Articles
